KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) EBIT Margin (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed EBIT Margin for 10 consecutive years, with 17912.5% as the latest value for Q4 2025.

  • Quarterly EBIT Margin fell 1773154.0% to 17912.5% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 18933.65% through Dec 2025, down 1768327.0% year-over-year, with the annual reading at 18933.65% for FY2025, 1768327.0% down from the prior year.
  • EBIT Margin hit 17912.5% in Q4 2025 for CRISPR Therapeutics AG, down from 14854.78% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 84.67% in Q2 2021 to a low of 2192350.0% in Q4 2022.
  • Historically, EBIT Margin has averaged 142655.16% across 5 years, with a median of 17912.5% in 2025.
  • Biggest five-year swings in EBIT Margin: plummeted -219122047bps in 2022 and later soared 219238458bps in 2023.
  • Year by year, EBIT Margin stood at 1129.53% in 2021, then crashed by -193994bps to 2192350.0% in 2022, then skyrocketed by 100bps to 34.58% in 2023, then tumbled by -623bps to 180.96% in 2024, then tumbled by -9798bps to 17912.5% in 2025.
  • Business Quant data shows EBIT Margin for CRSP at 17912.5% in Q4 2025, 14854.78% in Q3 2025, and 25708.97% in Q2 2025.